These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 24236720

  • 1. Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity.
    Koseki Y, Aoki S.
    Curr Top Med Chem; 2014; 14(1):176-88. PubMed ID: 24236720
    [Abstract] [Full Text] [Related]

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014 Dec; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 4. Tuberculosis: An Inorganic Medicinal Chemistry Perspective.
    Viganor L, Skerry C, McCann M, Devereux M.
    Curr Med Chem; 2015 Dec; 22(18):2199-224. PubMed ID: 25850770
    [Abstract] [Full Text] [Related]

  • 5. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS, Sasidhar BS, Nagaraja BM, Santos MA.
    Eur J Med Chem; 2015 Jul 15; 100():257-69. PubMed ID: 26112067
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M, Wan B, Cho S, Franzblau SG, Costantino G.
    Eur J Med Chem; 2014 Jan 24; 72():26-34. PubMed ID: 24333612
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH, Smith PW.
    Bioorg Med Chem; 2015 Aug 15; 23(16):5087-97. PubMed ID: 25577708
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
    Liu M, Grkovic T, Zhang L, Liu X, Quinn RJ.
    J Antibiot (Tokyo); 2016 Aug 15; 69(8):594-9. PubMed ID: 27406906
    [Abstract] [Full Text] [Related]

  • 11. Polypharmacology-Driven Discovery and Design of Highly Selective, Dual and Multitargeting Inhibitors of Mycobacterium tuberculosis - A Review.
    Amandy FV, Neri GLL, Manzano JAH, Go AD, Macabeo APG.
    Curr Drug Targets; 2024 Aug 15; 25(9):620-634. PubMed ID: 38859782
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents.
    Yan M, Xu L, Wang Y, Wan J, Liu T, Liu W, Wan Y, Zhang B, Wang R, Li Q.
    Drug Dev Res; 2020 Jun 15; 81(4):402-418. PubMed ID: 31904877
    [Abstract] [Full Text] [Related]

  • 19. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.
    de Souza MVN, Nogueira TCM.
    Curr Top Med Chem; 2019 Jun 15; 19(8):567-578. PubMed ID: 30834835
    [Abstract] [Full Text] [Related]

  • 20. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L, Hu X, Chai X, Ye Q, Pang J, Li D, Hou T.
    Drug Discov Today; 2022 Jan 15; 27(1):326-336. PubMed ID: 34537334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.